1,712.00
+32.00
+(1.90%)
At close: January 31 at 2:09:09 PM GMT+1
Research Analysis
Earnings Estimate
Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | -- | -- | -- | -- |
Avg. Estimate | 0 | 0 | 0 | 0 |
Low Estimate | 0 | 0 | 0 | 0 |
High Estimate | 0 | 0 | 0 | 0 |
Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | 26 | 25 | 50 | 52 |
Avg. Estimate | 68.46B | 72.63B | 277.38B | 316.72B |
Low Estimate | 67.14B | 71.47B | 274.86B | 304.21B |
High Estimate | 69.36B | 74.63B | 282.21B | 341.76B |
Year Ago Sales | 61.86B | 64.73B | 245.12B | 277.38B |
Sales Growth (year/est) | 10.68% | 12.21% | 13.16% | 14.18% |
EPS Trend
Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Current Estimate | 0 | 0 | 0 | 0 |
7 Days Ago | 0 | 0 | 0 | 0 |
30 Days Ago | 0 | 0 | 0 | 0 |
60 Days Ago | 0 | 0 | 0 | 0 |
90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
Current Qtr. | Next Qtr. | Current Year | Next Year | |
---|---|---|---|---|
MSFT.WA | -- | -- | -- | -- |
S&P 500 | 10.32% | 10.05% | 13.98% | 13.74% |
Upgrades & Downgrades
Maintains | UBS: Buy to Buy | 1/30/2025 |
Maintains | DA Davidson: Neutral to Neutral | 1/30/2025 |
Reiterates | RBC Capital: Outperform to Outperform | 1/30/2025 |
Maintains | Morgan Stanley: Overweight to Overweight | 1/30/2025 |
Maintains | Mizuho: Outperform to Outperform | 1/30/2025 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 1/29/2025 |